Urology Doctors in Willard, OH Accepting Medicare

1 Urology doctors found. Showing 1 - 1

Dr. Marvin Kazmin, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 110 E Howard St, Willard, OH 44890 Phone: 419-933-1333

News Archive

MGC Diagnostics third quarter total revenues increase 8% to $6.9 million

MGC Diagnostics Corporation, a global medical technology company, today reported financial results for the third quarter of fiscal year 2012, ended July 31, 2012.

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that results from a pre-clinical study showed significant improvement in the delivery and half life of Å6, a proprietary peptide treatment for ovarian cancer currently in Phase 2 development by Angstrom Pharmaceuticals. Specifically, the incorporation of NexACT® enabled the dose of Å6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model.

Update on Phase II clinical study of CH-4051 in rheumatoid arthritis

Chelsea Therapeutics International, Ltd. announced that during a teleconference yesterday, the U.S. Food and Drug Administration requested that the company delay the initiation of its proposed Phase II clinical study of CH-4051 in rheumatoid arthritis and indicated that the agency is requesting additional detail from the preclinical studies previously submitted as part of the company's investigational new drug application.

Role of society and business in advancing global efforts to fight climate change

Heads of state, United Nations agency heads and CEOs of the world's top businesses will gather in New York on Tuesday, September 22, at the United Nations Summit on Climate Change to explore the role business and society can play in advancing global efforts to fight climate change.

FDA accepts TxCell's IND application for Ovasave for treatment of refractory Crohn's disease

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell's Investigational New Drug application for the company's lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn's disease.

Read more Medical News

› Verified 6 days ago